REGEnLIFE focuses their therapeutic strategy on the brain-gut axis for the Alzheimer’s disease
Feb , 15
REGEnLIFE presentation selected for the highlights of the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) international conference